Confirmed Objective Response Rate (ORR) and Median Duration of Response (mDOR)

Studied in DESTINY-Gastric01,

40.5% achieved a confirmed ORR with ENHERTU1,a

Confirmed ORR with ENHERTU vs irinotecan or paclitaxel1,a

ENHERTU confirmed objective response rate ENHERTU confirmed objective response rate

aConfirmed ORR was defined as a response (CR+PR according to RECIST v1.1) as confirmed on a follow-up scan ≥4 weeks after an initial response as designated by ICR.2

ENHERTU demonstrated an 11.3-month mDOR1,b

mDOR in the ENHERTU arm vs the irinotecan or paclitaxel arm1,b

ENHERTU median duration of response ENHERTU median duration of response
  • DESTINY-Gastric01 studied 188 adult patients with HER2+ aGC who had received ≥2 prior lines of treatment, including a trastuzumab-based regimen

Median time to response with ENHERTU was 6 weeks2,c

  • 1.5 months (95% CI: 1.4, 1.7) TTR with ENHERTU and 1.6 months (95% CI: 1.3, 1.7) with irinotecan or paclitaxel
    • Median is from Kaplan-Meier estimate. CI for median is computed using the Brookmeyer-Crowley method

aGC, advanced gastric cancer; CI, confidence interval; CR, complete response; NR, not reached; PR, partial response; TTR, time to response; RECIST, Response Evaluation Criteria in Solid Tumors.

bmDOR was measured for responding patients (PR or CR) only (ENHERTU, n=51; irinotecan, n=6; paclitaxel, n=1).5

cExploratory endpoint.

Ready to learn more about ENHERTU?